A detailed history of Two Sigma Investments, LP transactions in Insmed Inc stock. As of the latest transaction made, Two Sigma Investments, LP holds 801,139 shares of INSM stock, worth $53.1 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares
801,139
Previous 107,744 643.56%
Holding current value
$53.1 Million
Previous $7.22 Million 710.24%
% of portfolio
0.14%
Previous 0.02%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$62.0 - $79.01 $43 Million - $54.8 Million
693,395 Added 643.56%
801,139 $58.5 Million
Q2 2024

Aug 14, 2024

SELL
$22.0 - $69.71 $7.75 Million - $24.6 Million
-352,429 Reduced 76.59%
107,744 $7.22 Million
Q1 2024

May 15, 2024

BUY
$25.72 - $29.94 $2.77 Million - $3.22 Million
107,561 Added 30.5%
460,173 $12.5 Million
Q4 2023

Feb 14, 2024

SELL
$23.42 - $31.74 $5.66 Million - $7.67 Million
-241,548 Reduced 40.65%
352,612 $10.9 Million
Q3 2023

Nov 14, 2023

BUY
$19.86 - $26.93 $2.09 Million - $2.84 Million
105,388 Added 21.56%
594,160 $15 Million
Q2 2023

Aug 14, 2023

BUY
$16.44 - $21.1 $526,934 - $676,297
32,052 Added 7.02%
488,772 $10.3 Million
Q1 2023

May 15, 2023

BUY
$16.26 - $21.73 $27,381 - $36,593
1,684 Added 0.37%
456,720 $7.79 Million
Q4 2022

Feb 14, 2023

BUY
$16.98 - $23.15 $2.69 Million - $3.67 Million
158,416 Added 53.41%
455,036 $9.09 Million
Q3 2022

Nov 14, 2022

BUY
$20.88 - $28.21 $6.19 Million - $8.37 Million
296,620 New
296,620 $6.39 Million
Q2 2022

Aug 15, 2022

SELL
$17.07 - $25.71 $474,546 - $714,738
-27,800 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$20.42 - $28.13 $6,126 - $8,439
300 Added 1.09%
27,800 $653,000
Q4 2021

Feb 14, 2022

SELL
$25.89 - $33.45 $7.97 Million - $10.3 Million
-307,709 Reduced 91.8%
27,500 $749,000
Q3 2021

Nov 15, 2021

BUY
$22.46 - $29.47 $1.39 Million - $1.83 Million
62,074 Added 22.73%
335,209 $9.23 Million
Q2 2021

Aug 16, 2021

BUY
$24.17 - $36.01 $1.17 Million - $1.75 Million
48,588 Added 21.64%
273,135 $7.77 Million
Q1 2021

May 17, 2021

BUY
$32.28 - $44.3 $6.81 Million - $9.34 Million
210,911 Added 1546.72%
224,547 $7.65 Million
Q4 2020

Feb 16, 2021

SELL
$31.45 - $40.54 $6.36 Million - $8.2 Million
-202,326 Reduced 93.69%
13,636 $454,000
Q3 2020

Nov 16, 2020

BUY
$26.0 - $34.5 $1.5 Million - $1.99 Million
57,671 Added 36.43%
215,962 $6.94 Million
Q2 2020

Aug 14, 2020

BUY
$14.11 - $29.42 $1.58 Million - $3.29 Million
111,736 Added 240.01%
158,291 $4.36 Million
Q1 2020

May 15, 2020

SELL
$13.63 - $33.98 $71,434 - $178,089
-5,241 Reduced 10.12%
46,555 $746,000
Q4 2019

Feb 14, 2020

SELL
$16.12 - $24.98 $3.08 Million - $4.77 Million
-191,141 Reduced 78.68%
51,796 $1.24 Million
Q3 2019

Nov 14, 2019

SELL
$15.49 - $25.78 $3.39 Million - $5.64 Million
-218,674 Reduced 47.37%
242,937 $4.29 Million
Q2 2019

Aug 14, 2019

BUY
$23.0 - $32.19 $8.49 Million - $11.9 Million
369,120 Added 399.09%
461,611 $11.8 Million
Q1 2019

May 15, 2019

BUY
$13.91 - $31.15 $806,487 - $1.81 Million
57,979 Added 168.0%
92,491 $2.69 Million
Q4 2018

Feb 14, 2019

SELL
$11.6 - $18.7 $46,017 - $74,182
-3,967 Reduced 10.31%
34,512 $453,000
Q3 2018

Nov 14, 2018

BUY
$18.95 - $28.08 $548,356 - $812,550
28,937 Added 303.26%
38,479 $778,000
Q2 2018

Aug 14, 2018

SELL
$20.0 - $29.72 $1.73 Million - $2.57 Million
-86,343 Reduced 90.05%
9,542 $226,000
Q1 2018

May 15, 2018

SELL
$21.69 - $32.99 $439,048 - $667,783
-20,242 Reduced 17.43%
95,885 $2.16 Million
Q4 2017

Feb 14, 2018

SELL
$26.43 - $31.78 $1.27 Million - $1.53 Million
-48,014 Reduced 29.25%
116,127 $3.62 Million
Q3 2017

Nov 14, 2017

BUY
$11.61 - $31.21 $1.91 Million - $5.12 Million
164,141
164,141 $5.12 Million

Others Institutions Holding INSM

About INSMED Inc


  • Ticker INSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,476,992
  • Market Cap $8.98B
  • Description
  • Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...
More about INSM
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.